Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;96(12):2991-3000.
doi: 10.1016/j.mayocp.2021.07.021. Epub 2021 Oct 30.

Treatment of Obesity: Pharmacotherapy Trends of Office-Based Visits in the United States From 2011 to 2016

Mechelle D Claridy  1 , Kathryn S Czepiel  2 , Simar S Bajaj  3 , Fatima Cody Stanford  4
Affiliations

Treatment of Obesity: Pharmacotherapy Trends of Office-Based Visits in the United States From 2011 to 2016

Mechelle D Claridy et al. Mayo Clin Proc. 2021 Dec.

Abstract

Objective: To examine pharmacotherapy for obesity in the United States from 2011 to 2016 using a large, nationally representative sample.

Methods: Data were obtained during 6 years, 2011 to 2016, from the National Ambulatory Medical Care Survey. There were 3 types of visits identified: patients with obesity and an antiobesity drug mention; patients with obesity and no antiobesity drug mention; and patients without obesity and with antiobesity drug mention. The χ2 test was used to compare characteristics across each type of visit. To predict the odds of an antiobesity medication mention for patients with obesity, a logistic regression analysis was conducted.

Results: Of the overall weighted 196,872,870 office-based physician visits made by patients with obesity from 2011 to 2016, 1% mentioned an antiobesity drug. In addition, there were 760,470 office-based physician visits by patients without obesity but with an antiobesity medication mention. An antiobesity drug mention was more likely for those aged 51 years or older and those residing in the South (adjusted odds ratio, 5.31 95% CI, 1.19 to 23.59).

Conclusion: There was a slight increase in antiobesity medication mentions, from 0.26% in 2011 to 0.28% in 2016, but only 1% of office-based visits for patients with obesity received a prescription for an antiobesity medication. Physicians tended to prescribe antiobesity medications to those with obesity aged 51 years or older and residing in the South. Antiobesity medication for treatment of obesity is significantly underused.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosure

The authors have no conflicts of interest to disclose. This article has not been published or submitted for publication elsewhere.

Figures

Figure 1.
Figure 1.
Trend in number of anti-obesity medication prescriptions by two-year period from 2011 to 2016
See this image and copyright information in PMC

Comment in

References

    1. Adult Obesity Facts. Overweight and Obesity Web site. https://www.cdc.gov/obesity/data/adult.html. Updated 11 February 2021. Accessed 13 February 2021.
    1. Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med. 2019;381(25):2440–2450. - PubMed
    1. Xia Y, Kelton CM, Guo JJ, Bian B, Heaton PC. Treatment of obesity: Pharmacotherapy trends in the United States from 1999 to 2010. Obesity (Silver Spring). 2015;23(8):1721–1728. - PubMed
    1. Thomas CE, Mauer EA, Shukla AP, Rathi S, Aronne LJ. Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s. Obesity (Silver Spring). 2016;24(9):1955–1961. - PMC - PubMed
    1. Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. The Lancet Diabetes & Endocrinology. 2018;6(3):237–248. - PubMed

Publication types

Substances